EICHORCondition: Depressive Disorder, Major · Sponsor: Usona Institute
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama Clinical Research Unit | Birmingham, Alabama, United States | — |
| Preferred Research Partners-NWA, LLC | Fayetteville, Arkansas, United States | — |
| Preferred Research Partners, Inc. | Little Rock, Arkansas, United States | — |
| Kadima Neuropsychiatry Institute | La Jolla, California, United States | — |
| West LA VA Medical Center - Mental Health Department | Los Angeles, California, United States | — |
| Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners | Santa Monica, California, United States | — |
| Psychedelic Science Institute | Santa Monica, California, United States | — |
| Mountain View Clinical Research | Denver, Colorado, United States | — |
| Connecticut Mental Health Center, Yale University | New Haven, Connecticut, United States | — |
| Clinical Neuroscience Solutions Inc. | Jacksonville, Florida, United States | — |
| Innovative Clinical Research, Inc. | Lauderhill, Florida, United States | — |
| Clinical Neuroscience Solutions, Inc. | Orlando, Florida, United States | — |
+ 17 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06308653